Results 161 to 170 of about 6,619 (182)
Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. [PDF]
Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD).
Paul B Watkins +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease
Drugs, 2015Hannah A Blair, Gillian M Keating
exaly
Mechanisms of Tolvaptan-Induced Toxicity in HepG2 Cells
Biochemical Pharmacology, 2015Yuanfeng Wu +2 more
exaly
Tolvaptan, an Oral Vasopressin Antagonist, in the Treatment of Hyponatremia in Cirrhosis
Journal of Hepatology, 2012Andres Cardenas +2 more
exaly

